Stammdaten
Disc Medicine, Inc., ein klinisches Biotechnologie-Unternehmen, ist in der Entdeckung, Entwicklung und Kommerzialisierung neuartiger Behandlungen für Patienten mit ernsthaften hämatologischen Erkrankungen tätig. Es entwickelt ein Portfolio therapeutischer Kandidaten, das ein Spektrum hämatologischer Erkrankungen durch Anvisierung grundlegender biologischer Wege der Erythrozytenbiologie adressiert, hauptsächlich Häm-Biosynthese und Eisenhomöostase. Das Unternehmen hat seinen Sitz in Watertown, Massachusetts. KI
Unternehmen & Branche
| Name | Disc Medicine, Inc. |
|---|---|
| Ticker | IRON |
| CIK | 0001816736 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 254604101 |
|---|---|
| ISIN | US2546041011 |
| Typ | Common Stock |
| Marktkapitalisierung | 2,81 Mrd. USD |
| Beta | 0,98 |
Sitz & Kontakt
| Geschäftsadresse | 321 ARSENAL STREET, SUITE 101, 02472 WATERTOWN, MA |
|---|---|
| Telefon | (617) 674-9274 |
| EIN (IRS) | 85-1612845 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | Gemini Therapeutics, Inc. /DE (bis 2022) FS Development Corp. (bis 2021) |
Bewertung
| KBV (P/B) | 3,80 |
|---|---|
| FCF-Rendite | -6,5 % vs. -104,3 % (2021) ▲ |
Qualität & Bilanz
| ROIC | -27,5 % |
|---|---|
| Zinsdeckungsgrad | -65,4 vs. -14,3 (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | – | 1,96 | 4,08 | 4,27 | 4,07 | 4,08 | |
| FCF-Rendite | -104,3 % | -12,2 % | -5,2 % | -5,0 % | -6,0 % | -7,2 % | |
| Qualität & Bilanz | |||||||
| ROIC | – | -26,3 % | -22,0 % | -23,1 % | -27,5 % | -33,6 % | |
| Zinsdeckungsgrad | -14,3 | – | – | -226,8 | -65,4 | -74,7 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
IRON
Disc Medicine, Inc.
Effektiv
Schwach
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
36,4
43 neu, 82 erhöht, -381712K $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 71.74 | +4.0 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 74.66 | -0.1 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 74.72 | EMA50: 72.66 | |
| MACD-Histogramm | Bärisch | 10 % | -0.460 | Bearisch | |
| RSI(14) | Neutral | 10 % | 51.1 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 26.2 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 14.8 | +DI: 16.3 / −DI: 14.9 | |
| Z-Score(60) | Neutral | 5 % | 0.91 | In Range | |
| 52W-Position | Neutral | 5 % | 48.9 % | Hoch 94.11 / Tief 55.95 | |
| Bollinger(20,2σ) | Neutral | 5 % | 33.6 % | Upper 79.58 / Mid 75.84 / Lower 72.09 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1808 | R²=0.66 / annualisiert +64.1 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-13 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -16.896 | 74,95 | -1.266.302,82 | -105,6% | |
| 2026-07-13 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -9.704 | 74,27 | -720.744,22 | -60,1% | |
| 2026-07-13 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -6.400 | 76,05 | -486.732,80 | -40,6% | |
| 2026-07-07 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -100 | 82,50 | -8.250,00 | -0,7% | |
| 2026-06-29 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -1.649 | 75,00 | -123.675,00 | -10,3% | |
| 2026-06-26 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -300 | 72,50 | -21.750,00 | -1,8% | |
| 2026-06-26 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -851 | 75,00 | -63.825,00 | -5,3% | |
| 2026-06-22 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -9.700 | 72,66 | -704.795,21 | -58,8% | |
| 2026-06-18 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -1.551 | 71,61 | -111.071,14 | -9,3% | |
| 2026-06-18 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -5.400 | 69,94 | -377.688,42 | -31,5% | |
| 2026-06-18 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -1.600 | 70,73 | -113.161,12 | -9,4% | |
| 2026-06-18 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -500 | 71,62 | -35.811,00 | -3,0% | |
| 2026-06-18 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -22.927 | 69,92 | -1.603.019,16 | -133,7% | |
| 2026-06-18 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -9.522 | 70,70 | -673.205,40 | -56,1% | |
| 2026-06-16 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -6.961 | 69,92 | -486.699,20 | -40,6% | |
| 2026-06-16 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -11.651 | 68,76 | -801.101,79 | -66,8% | |
| 2026-04-14 | Franchi Jean M. | Officer, Chief Financial Officer | Open Market Sale | -6.257 | 69,24 | -433.234,05 | -36,1% | |
| 2026-04-13 | Franchi Jean M. | Officer, Chief Financial Officer | Open Market Sale | -400 | 69,00 | -27.600,00 | -2,3% | |
| 2026-04-13 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -3.531 | 66,12 | -233.472,90 | -19,5% | |
| 2026-04-13 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -2.200 | 66,81 | -146.976,06 | -12,3% | |
| 2026-03-02 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -4.392 | 65,52 | -287.771,75 | -24,0% | |
| 2026-03-02 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -2.986 | 66,41 | -198.297,27 | -16,5% | |
| 2026-02-25 | Franchi Jean M. | Officer, Chief Financial Officer | Open Market Sale | -353 | 69,06 | -24.377,09 | -2,0% | |
| 2026-02-18 | Franchi Jean M. | Officer, Chief Financial Officer | Open Market Sale | -3.684 | 65,89 | -242.734,71 | -20,2% | |
| 2026-02-18 | Franchi Jean M. | Officer, Chief Financial Officer | Open Market Sale | -3.397 | 65,01 | -220.837,95 | -18,4% | |
| 2026-02-17 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -3.256 | 62,86 | -204.672,16 | -17,1% | |
| 2026-02-17 | Stephenson Pamela | Officer, Chief Commercial Officer | Open Market Sale | -5.531 | 62,86 | -347.678,66 | -29,0% | |
| 2026-02-17 | Franchi Jean M. | Officer, Chief Financial Officer | Open Market Sale | -4.075 | 62,86 | -256.154,50 | -21,4% | |
| 2026-02-17 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -13.264 | 62,86 | -833.775,04 | -69,5% | |
| 2026-02-17 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -3.231 | 62,86 | -203.100,66 | -16,9% | |
| 2026-02-17 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -2.853 | 62,86 | -179.339,58 | -15,0% | |
| 2026-01-20 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -1.000 | 69,74 | -69.740,00 | -5,8% | |
| 2026-01-02 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -1.157 | 79,27 | -91.717,70 | -7,6% | |
| 2026-01-02 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -350 | 77,67 | -27.184,92 | -2,3% | |
| 2026-01-02 | Khara Rahul | Officer, Chief Legal Officer | Open Market Sale | -4.993 | 78,62 | -392.569,13 | -32,7% | |
| 2025-12-17 | Bitterman Kevin | Director | Open Market Sale | -213 | 91,47 | -19.483,11 | -1,6% | |
| 2025-12-17 | Bitterman Kevin | Director | Open Market Sale | -393 | 91,47 | -35.947,71 | -3,0% | |
| 2025-12-17 | Bitterman Kevin | Director | Open Market Sale | -148 | 91,47 | -13.537,56 | -1,1% | |
| 2025-12-16 | Bitterman Kevin | Director | Open Market Sale | -14.359 | 91,24 | -1.310.115,16 | -109,2% | |
| 2025-12-16 | Bitterman Kevin | Director | Open Market Sale | -35.898 | 91,24 | -3.275.333,52 | -273,1% | |
| 2025-12-16 | Bitterman Kevin | Director | Open Market Sale | -18.666 | 91,24 | -1.703.085,84 | -142,0% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -2.049 | 92,01 | -188.528,49 | -15,7% | |
| 2025-12-15 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -300 | 92,23 | -27.669,00 | -2,3% | |
| 2025-12-15 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -3.642 | 90,60 | -329.978,68 | -27,5% | |
| 2025-12-15 | Savage William Jacob | Officer, Chief Medical Officer | Open Market Sale | -9.151 | 91,44 | -836.724,43 | -69,8% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -1.572 | 92,01 | -144.639,72 | -12,1% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -3.921 | 92,01 | -360.771,21 | -30,1% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -7.000 | 91,87 | -643.090,00 | -53,6% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -11.427 | 91,18 | -1.041.913,86 | -86,9% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -14.811 | 91,18 | -1.350.466,98 | -112,6% | |
| 2025-12-15 | Bitterman Kevin | Director | Open Market Sale | -28.913 | 91,18 | -2.636.287,34 | -219,8% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -1.371 | 93,80 | -128.599,80 | -10,7% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -16.403 | 92,05 | -1.509.896,15 | -125,9% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -8.527 | 92,05 | -784.910,35 | -65,5% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -6.570 | 92,05 | -604.768,50 | -50,4% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -3.852 | 92,58 | -356.618,16 | -29,7% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -3.446 | 93,80 | -323.234,80 | -27,0% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -2.005 | 92,58 | -185.622,90 | -15,5% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -1.793 | 93,80 | -168.183,40 | -14,0% | |
| 2025-12-12 | Bitterman Kevin | Director | Open Market Sale | -1.540 | 92,58 | -142.573,20 | -11,9% | |
| 2025-12-11 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -4.337 | 92,21 | -399.919,97 | -33,3% | |
| 2025-12-11 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -16.888 | 93,65 | -1.581.549,38 | -131,9% | |
| 2025-12-11 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -16.356 | 92,96 | -1.520.398,15 | -126,8% | |
| 2025-12-11 | Quisel John D | Director, Officer, Chief Executive Officer | Open Market Sale | -2.419 | 90,97 | -220.063,69 | -18,4% | |
| 2025-11-11 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -4.585 | 83,99 | -385.083,60 | -32,1% | |
| 2025-11-11 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -9.360 | 85,33 | -798.689,74 | -66,6% | |
| 2025-11-11 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -8.040 | 85,91 | -690.739,72 | -57,6% | |
| 2025-11-11 | Yu Jonathan Yen-Wen | Officer, Chief Operating Officer | Open Market Sale | -8.015 | 83,15 | -666.409,58 | -55,6% | |
| 2025-10-22 | AI DMI LLC | 10% Owner | Open Market Sale | -744.047 | 80,47 | -59.873.462,09 | -4992,6% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -1.125 | 84,89 | -95.501,25 | -8,0% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -13.014 | 88,91 | -1.157.074,74 | -96,5% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -10.095 | 90,66 | -915.212,70 | -76,3% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -10.094 | 90,66 | -915.122,04 | -76,3% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -5.066 | 87,37 | -442.616,42 | -36,9% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -5.065 | 87,37 | -442.529,05 | -36,9% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -3.000 | 86,13 | -258.390,00 | -21,5% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -2.251 | 89,70 | -201.914,70 | -16,8% | |
| 2025-10-17 | Bitterman Kevin | Director | Open Market Sale | -450 | 91,88 | -41.346,00 | -3,4% | |
| 2025-10-16 | Bitterman Kevin | Director | Open Market Sale | -1.425 | 77,11 | -109.881,75 | -9,2% | |
| 2025-10-15 | Bitterman Kevin | Director | Open Market Sale | -19.542 | 77,16 | -1.507.860,72 | -125,7% | |
| 2025-10-15 | Bitterman Kevin | Director | Open Market Sale | -2.618 | 77,76 | -203.575,68 | -17,0% | |
| 2025-10-08 | Bitterman Kevin | Director | Open Market Sale | -12.689 | 71,51 | -907.390,39 | -75,7% | |
| 2025-10-08 | Bitterman Kevin | Director | Open Market Sale | -8.219 | 68,26 | -561.028,94 | -46,8% | |
| 2025-10-08 | Bitterman Kevin | Director | Open Market Sale | -12.386 | 69,31 | -858.473,66 | -71,6% | |
| 2025-10-08 | Bitterman Kevin | Director | Open Market Sale | -25.400 | 70,54 | -1.791.716,00 | -149,4% | |
| 2025-10-08 | Bitterman Kevin | Director | Open Market Sale | -13.267 | 72,39 | -960.398,13 | -80,1% | |
| 2025-10-07 | Bitterman Kevin | Director | Open Market Sale | -6.661 | 69,01 | -459.675,61 | -38,3% | |
| 2025-10-07 | Bitterman Kevin | Director | Open Market Sale | -11.378 | 68,01 | -773.817,78 | -64,5% | |
| 2025-08-22 | Bitterman Kevin | Director | Open Market Sale | -2.287 | 61,03 | -139.575,61 | -11,6% | |
| 2025-08-14 | Bitterman Kevin | Director | Open Market Sale | -7.212 | 60,99 | -439.859,88 | -36,7% | |
| 2025-08-13 | Bitterman Kevin | Director | Open Market Sale | -24.962 | 61,15 | -1.526.426,30 | -127,3% | |
| 2025-08-05 | Bitterman Kevin | Director | Open Market Sale | -395 | 60,95 | -24.075,25 | -2,0% | |
| 2025-07-30 | Bitterman Kevin | Director | Open Market Sale | -8.492 | 61,04 | -518.351,68 | -43,2% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 5.586.894 | 0 | 5.586.894 | 357.226.003 | Neu | +100,0% | |
| RA CAPITAL MANAGEMENT, L.P. | 2.450.221 | 0 | 2.450.221 | 156.667.131 | Neu | +100,0% | |
| BlackRock, Inc. | 2.273.831 | 0 | 2.273.831 | 145.388.755 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.735.376 | 0 | 1.735.376 | 110.959.941 | Neu | +100,0% | |
| STATE STREET CORP | 1.698.244 | 0 | 1.698.244 | 108.585.721 | Neu | +100,0% | |
| Atlas Venture Life Science Advisors, LLC | 1.513.875 | 0 | 1.513.875 | 96.797.168 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.375.430 | 0 | 1.375.430 | 87.944.994 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 1.354.852 | 0 | 1.354.852 | 86.629.237 | Neu | +100,0% | |
| TCG Crossover Management, LLC | 1.341.862 | 0 | 1.341.862 | 85.798.656 | Neu | +100,0% | |
| BVF INC/IL | 1.272.312 | 0 | 1.272.312 | 81.351.629 | Neu | +100,0% | |
| ORBIMED ADVISORS LLC | 1.067.550 | 0 | 1.067.550 | 68.259.147 | Neu | +100,0% | |
| Siren, L.L.C. | 988.401 | 0 | 988.401 | 63.198.360 | Neu | +100,0% | |
| Woodline Partners LP | 958.281 | 0 | 958.281 | 61.272.487 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 744.222 | 0 | 744.222 | 47.595.151 | Neu | +100,0% | |
| Vestal Point Capital, LP | 700.000 | 0 | 700.000 | 44.758.000 | Neu | +100,0% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 657.000 | 0 | 657.000 | 42.008.580 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 639.842 | 0 | 639.842 | 40.911.498 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 610.382 | 0 | 610.382 | 39.027.825 | Neu | +100,0% | |
| Logos Global Management LP | 560.000 | 0 | 560.000 | 35.806.400 | Neu | +100,0% | |
| ARMISTICE CAPITAL, LLC | 536.000 | 0 | 536.000 | 34.271.840 | Neu | +100,0% | |
| Bellevue Group AG | 459.314 | 0 | 459.314 | 29.368.537 | Neu | +100,0% | |
| Saturn V Capital Management LP | 449.926 | 0 | 449.926 | 28.768.268 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 384.158 | 546.247 | -162.089 | 28.097.316 | Reduziert | -29,7% | |
| Opaleye Management Inc. | 421.000 | 0 | 421.000 | 26.918.740 | Neu | +100,0% | |
| Palo Alto Investors LP | 401.719 | 0 | 401.719 | 25.685.913 | Neu | +100,0% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 395.572 | 0 | 395.572 | 25.291.821 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 394.447 | 0 | 394.447 | 25.212.293 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 387.005 | 0 | 387.005 | 24.745.100 | Neu | +100,0% | |
| Aberdeen Group plc | 375.614 | 0 | 375.614 | 24.016.759 | Neu | +100,0% | |
| Foresite Capital Management V, LLC | 374.069 | 0 | 374.069 | 23.917.972 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 349.657 | 0 | 349.657 | 22.357.069 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 317.222 | 0 | 317.222 | 20.283.174 | Neu | +100,0% | |
| Caption Management, LLC | 300.000 | 0 | 300.000 | 19.182.000 | Neu | +100,0% | |
| Checkpoint Capital L.P. | 286.661 | 0 | 286.661 | 18.329.104 | Neu | +100,0% | |
| Octagon Capital Advisors LP | 270.000 | 0 | 270.000 | 17.263.800 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 251.195 | 0 | 251.195 | 16.061.408 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 247.195 | 0 | 247.195 | 15.805.648 | Neu | +100,0% | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 196.028 | 0 | 196.028 | 12.534.030 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 191.487 | 0 | 191.487 | 12.243.679 | Neu | +100,0% | |
| Integral Health Asset Management, LLC | 170.000 | 0 | 170.000 | 10.869.800 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 166.775 | 0 | 166.775 | 10.663.592 | Neu | +100,0% | |
| Bain Capital Life Sciences Investors, LLC | 141.234 | 0 | 141.234 | 9.030.502 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 131.130 | 0 | 131.130 | 8.384.452 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 127.737 | 0 | 127.737 | 8.167.504 | Neu | +100,0% | |
| Alyeska Investment Group, L.P. | 125.000 | 0 | 125.000 | 7.992.500 | Neu | +100,0% | |
| Catalio Capital Management, LP | 122.978 | 0 | 122.978 | 7.863.213 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 110.890 | 0 | 110.890 | 7.090.307 | Neu | +100,0% | |
| KENNEDY CAPITAL MANAGEMENT LLC | 108.286 | 0 | 108.286 | 6.923.807 | Neu | +100,0% | |
| UBS Group AG | 98.621 | 0 | 98.621 | 6.305.827 | Neu | +100,0% | |
| DnB Asset Management AS | 96.755 | 0 | 96.755 | 6.186.515 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 384.158 | 546.247 | -29,7% | 28.097.316 | 78,37 | 100 % | 10 Q |
| Atle Fund Management AB | 43.682 | 107.255 | -59,3% | 3.194.901 | 8,91 | 100 % | 5 Q |
| Y-Intercept (Hong Kong) Ltd | 26.888 | 0 | +100,0% | 1.966.588 | 5,48 | 100 % | 6 Q |
| Police & Firemen's Retirement System of New Jersey | 8.345 | 7.474 | +11,7% | 610.353 | 1,70 | 100 % | 7 Q |
| China Universal Asset Management Co., Ltd. | 8.239 | 8.372 | -1,6% | 602.600 | 1,68 | 100 % | 11 Q |
| PSP Research LLC | 8.000 | 8.000 | 0,0% | 585.120 | 1,63 | 0 % | 2 Q |
| Eleva Capital SAS | 5.115 | 5.115 | 0,0% | 327.053 | 0,91 | – | 2 Q |
| AlphaCentric Advisors LLC | 4.030 | 3.972 | +1,5% | 294.754 | 0,82 | 0 % | 3 Q |
| Mirae Asset Global Investments Co., Ltd. | 1.708 | 1.990 | -14,2% | 124.923 | 0,35 | 100 % | 9 Q |
| GAMMA Investing LLC | 292 | 268 | +9,0% | 21.357 | 0,06 | 100 % | 10 Q |
| Sterling Capital Management LLC | 99 | 178 | -44,4% | 7.241 | 0,02 | 0 % | 8 Q |
| CoreCap Advisors, LLC | 78 | 0 | +100,0% | 5.705 | 0,02 | 0 % | 3 Q |
| iA Global Asset Management Inc. | 66.023 | 66.243 | -0,3% | 4.829 | 0,01 | – | 5 Q |
| Farther Finance Advisors, LLC | 47 | 44 | +6,8% | 3.439 | 0,01 | 0 % | 4 Q |
| FIRST HORIZON CORP | 36 | 30 | +20,0% | 2.633 | 0,01 | 0 % | 3 Q |
| Versant Capital Management, Inc | 30 | 19 | +57,9% | 2.194 | 0,01 | 100 % | 5 Q |
| EverSource Wealth Advisors, LLC | 17 | 71 | -76,1% | 1.243 | 0,00 | 100 % | 6 Q |
| Handelsbanken Fonder AB | 12.700 | 0 | +100,0% | 929 | 0,00 | 0 % | 1 Q |
| Bare Financial Services, Inc | 9 | 9 | 0,0% | 658 | 0,00 | 100 % | 4 Q |
| Hughes Financial Services, LLC | 2 | 1 | +100,0% | 146 | 0,00 | 100 % | 3 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 24 | 0,6 | 36 |
| 31.03.2026 | ✓ | 202 | 44,2 | 2.709 |
| 31.12.2025 | ✓ | 195 | 39,1 | 2.954 |
| 30.09.2025 | ✓ | 166 | 35,2 | 2.228 |
| 30.06.2025 | ✓ | 149 | 34,1 | 1.709 |
| 31.03.2025 | ✓ | 152 | 34,8 | 1.660 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| TCG Crossover Management, LLC | 1.341.862 | 85.798.656 |
| Bellevue Group AG | 459.314 | 29.368.537 |
| Octagon Capital Advisors LP | 270.000 | 17.263.800 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 196.028 | 12.534.030 |
| Integral Health Asset Management, LLC | 170.000 | 10.869.800 |
| Bain Capital Life Sciences Investors, LLC | 141.234 | 9.030.502 |
| Jump Financial, LLC | 81.829 | 5.232.146 |
| Freestone Grove Partners LP | 68.687 | 4.391.847 |
| Casdin Capital, LLC | 65.000 | 4.156.100 |
| MOORE CAPITAL MANAGEMENT, LP | 57.796 | 3.695.476 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| BVF INC/IL | 1.272.312 | 622.312 | +95.7 % | 81.351.629 |
| STATE STREET CORP | 1.698.244 | 510.253 | +43.0 % | 108.585.721 |
| RA CAPITAL MANAGEMENT, L.P. | 2.450.221 | 474.089 | +24.0 % | 156.667.131 |
| Opaleye Management Inc. | 421.000 | 221.000 | +110.5 % | 26.918.740 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.735.376 | 217.102 | +14.3 % | 110.959.941 |
| Assenagon Asset Management S.A. | 546.247 | 188.411 | +52.7 % | 34.927.033 |
| DIMENSIONAL FUND ADVISORS LP | 394.447 | 170.872 | +76.4 % | 25.212.293 |
| Saturn V Capital Management LP | 449.926 | 151.497 | +50.8 % | 28.768.268 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 657.000 | 145.837 | +28.5 % | 42.008.580 |
| Aberdeen Group plc | 375.614 | 141.256 | +60.3 % | 24.016.759 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Checkpoint Capital L.P. | 286.661 | -166.331 | -36.7 % | 18.329.104 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.549.350 | -148.655 | -8.8 % | 99.067 |
| GOLDMAN SACHS GROUP INC | 639.842 | -114.353 | -15.2 % | 40.911.498 |
| Nantahala Capital Management, LLC | 25.653 | -107.147 | -80.7 % | 1.640.253 |
| MILLENNIUM MANAGEMENT LLC | 83.259 | -101.520 | -54.9 % | 5.323.580 |
| BARCLAYS PLC | 33.267 | -66.345 | -66.6 % | 2.127.091 |
| VICTORY CAPITAL MANAGEMENT INC | 29.218 | -47.120 | -61.7 % | 1.868.199 |
| TD ASSET MANAGEMENT INC | 30.476 | -39.158 | -56.2 % | 1.948.635 |
| RAYMOND JAMES FINANCIAL INC | 44.700 | -35.574 | -44.3 % | 2.730.523 |
| TUDOR INVESTMENT CORP ET AL | 31.002 | -35.123 | -53.1 % | 1.982.268 |
Zusätzlich aktuell von 127 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 07.01.2026 | RA Capital Healthcare Fund, L.P. (+3) | Passiv (13G) | 5,90 % | 2.228.924 | Neu | – | |
| 17.12.2025 | Atlas Venture Associates XII, L.P. (+2) | Aktivist (13D/A) | 0,00 % | 14.013 | -0,10 pp | – | |
| 17.12.2025 | ATLAS VENTURE ASSOCIATES X, L.P. (+2) | Aktivist (13D/A) | 2,20 % | 813.167 | -0,90 pp | – | |
| 17.12.2025 | Atlas Venture Associates Opportunity I, L.P. (+2) | Aktivist (13D/A) | 0,90 % | 349.210 | -0,80 pp | – | |
| 17.12.2025 | Atlas Venture Associates Opportunity II, LLC (+2) | Aktivist (13D/A) | 0,90 % | 337.485 | -0,30 pp | – | |
| 05.11.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 14,10 % | 4.907.159 | +1,90 pp | – | |
| 22.10.2025 | Access Industries Management, LLC (+3) | Aktivist (13D/A) | 8,00 % | 3.018.460 | -2,80 pp | The disclosure in Item 4 to the Schedule is hereby supplemented by adding the following … | |
| 15.08.2025 | ATLAS VENTURE ASSOCIATES X, L.P. (+2) | Aktivist (13D/A) | 3,10 % | 1.084.527 | Neu | – | |
| 15.08.2025 | Atlas Venture Associates Opportunity II, LLC (+2) | Aktivist (13D/A) | 1,20 % | 420.549 | Neu | – | |
| 15.08.2025 | Atlas Venture Associates XII, L.P. (+2) | Aktivist (13D/A) | 0,10 % | 51.000 | Neu | – | |
| 15.08.2025 | Atlas Venture Associates Opportunity I, L.P. (+2) | Aktivist (13D/A) | 1,70 % | 592.908 | Neu | – | |
| 14.08.2025 | Frazier Life Sciences Public Overage Fund, L.P. (+2) | Passiv (13G/A) | 0,90 % | 300.643 | Neu | – | |
| 14.08.2025 | Frazier Life Sciences XI, L.P. (+2) | Passiv (13G/A) | 0,80 % | 264.484 | Neu | – | |
| 14.08.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Passiv (13G/A) | 3,00 % | 1.026.489 | Neu | – | |
| 14.08.2025 | Daniel Estes (+2) | Passiv (13G/A) | Ausstieg | 0 | Neu | – | |
| 14.08.2025 | Frazier Life Sciences X, L.P. (+4) | Passiv (13G/A) | 0,20 % | 63.218 | Neu | – | |
| 12.08.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 4,10 % | 1.432.090 | -2,70 pp | – | |
| 07.08.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 12,20 % | 4.221.058 | +2,90 pp | – | |
| 15.05.2025 | Paradigm BioCapital International Fund Ltd. | Passiv (13G/A) | 3,10 % | 1.069.143 | -1,20 pp | – | |
| 15.05.2025 | Paradigm BioCapital Advisors GP LLC (+2) | Passiv (13G/A) | 3,50 % | 1.210.971 | -1,54 pp | – | |
| 12.05.2025 | Wellington Management Company LLP | Passiv (13G) | 6,40 % | 2.343.499 | +0,59 pp | – | |
| 12.05.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G) | 6,80 % | 2.343.499 | +2,10 pp | – | |
| 12.05.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 9,30 % | 3.224.381 | +3,00 pp | – | |
| 12.03.2025 | ORBIMED ADVISORS LLC | Aktivist (13D/A) | 4,50 % | 1.556.369 | Neu | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 12.03.2025 | OrbiMed Genesis GP LLC | Aktivist (13D/A) | 0,60 % | 205.175 | -0,20 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 12.03.2025 | OrbiMed Capital GP VIII LLC | Aktivist (13D/A) | 2,40 % | 820.707 | -0,80 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 12.03.2025 | ORBIMED CAPITAL GP VI LLC | Aktivist (13D/A) | 1,50 % | 530.487 | Neu | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 03.03.2025 | Access Industries Management, LLC (+3) | Aktivist (13D/A) | 10,80 % | 3.762.507 | -2,94 pp | – | |
| 14.02.2025 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 3,30 % | 983.500 | -6,69 pp | – | |
| 12.02.2025 | Abigail P. Johnson (+1) | Passiv (13G) | 6,30 % | 1.866.248 | Neu | – | |
| 10.02.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 4,70 % | 1.395.405 | -1,49 pp | – | |
| 14.11.2024 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 6,00 % | 1.795.735 | +0,50 pp | – | |
| 14.11.2024 | Paradigm BioCapital Advisors GP LLC (+2) | Passiv (13G/A) | 5,04 % | 1.497.720 | -4,86 pp | – | |
| 14.11.2024 | Paradigm BioCapital International Fund Ltd. | Passiv (13G/A) | 4,30 % | 1.285.282 | -4,10 pp | – | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G) | 6,20 % | 1.851.171 | 0,00 pp | – | |
| 08.11.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G) | 6,19 % | 1.840.226 | +6,19 pp | – | |
| 08.11.2024 | Wellington Management Company LLP | Passiv (13G) | 5,81 % | 1.726.738 | Neu | – | |
| 24.10.2024 | . BlackRock, Inc. | Passiv (13G) | 6,20 % | 1.851.171 | Neu | – | |
| 25.06.2024 | Frazier Life Sciences XI, L.P. (+3) | Passiv (13G) | 0,90 % | 280.484 | Neu | – | |
| 25.06.2024 | Frazier Life Sciences Public Fund, L.P. (+2) | Passiv (13G) | 3,70 % | 1.088.489 | Neu | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -63.504.000 $ | -1,65 $ | 750.213.000 $ | 688.429.000 $ |
| 2025-12-31 | 10-K | – | -212.184.000 $ | -6,01 $ | 806.879.000 $ | 739.826.000 $ |
| 2025-09-30 | 10-Q | – | -62.321.000 $ | -1,77 $ | 630.456.000 $ | 573.391.000 $ |
| 2025-06-30 | 10-Q | – | -55.247.000 $ | -1,58 $ | 665.061.000 $ | 614.165.000 $ |
| 2025-03-31 | 10-Q | – | -34.085.000 $ | -1,02 $ | 709.266.000 $ | 660.362.000 $ |
| 2024-12-31 | 10-K | – | -109.357.000 $ | -3,96 $ | 496.773.000 $ | 443.587.000 $ |
| 2024-09-30 | 10-Q | – | -26.599.000 $ | -0,89 $ | 495.145.000 $ | 467.960.000 $ |
| 2024-06-30 | 10-Q | – | -26.352.000 $ | -1,03 $ | 510.217.000 $ | 488.829.000 $ |
| 2024-03-31 | 10-Q | – | -26.949.000 $ | -1,09 $ | 354.182.000 $ | 338.071.000 $ |
| 2023-12-31 | 10-K | – | -76.429.000 $ | -3,42 $ | 367.996.000 $ | 345.121.000 $ |
| 2023-09-30 | 10-Q | – | -14.122.000 $ | -0,58 $ | 376.497.000 $ | 358.974.000 $ |
| 2023-06-30 | 10-Q | – | -15.947.000 $ | -0,74 $ | 384.174.000 $ | 371.219.000 $ |
| 2023-03-31 | 10-Q | – | -22.781.000 $ | -1,20 $ | 243.780.000 $ | 232.855.000 $ |
| 2022-12-31 | 10-K | – | -46.827.000 $ | -45,05 $ | 200.205.000 $ | 176.600.000 $ |
| 2022-09-30 | 10-Q | – | -16.150.000 $ | -16,82 $ | 106.031.000 $ | -98.527.000 $ |
| 2022-06-30 | 10-Q | – | -9.580.000 $ | -10,14 $ | 113.333.000 $ | -82.781.000 $ |
| 2022-03-31 | 10-Q | – | -9.853.000 $ | -10,67 $ | 124.285.000 $ | -73.669.000 $ |
| 2021-12-31 | 10-K | – | -35.969.000 $ | -40,95 $ | 92.411.000 $ | -64.203.000 $ |
| 2021-09-30 | 10-Q | – | -18.551.000 $ | -0,43 $ | 155.535.000 $ | 140.861.000 $ |
| 2021-06-30 | 10-Q | – | -16.447.000 $ | -0,38 $ | 172.422.000 $ | 157.682.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | – | -1,65 |
| Q3 2025 | 30.09.2025 | 06.11.2025 | – | -1,77 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | – | -1,58 |
| Q1 2025 | 31.03.2025 | 07.05.2025 | – | -1,02 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | – | -0,89 |
| Q2 2024 | 30.06.2024 | 08.08.2024 | – | -1,03 |
| Q1 2024 | 31.03.2024 | 09.05.2024 | – | -1,09 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | – | -0,58 |
| Q2 2023 | 30.06.2023 | 11.08.2023 | – | -0,74 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 06.11.2025 | 10-Q | 30.09.2025 | 37 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 07.05.2025 | 10-Q | 31.03.2025 | 37 Tage | SEC » |
| 27.02.2025 | 10-K | 31.12.2024 | 58 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 09.05.2024 | 10-Q | 31.03.2024 | 39 Tage | SEC » |
| 21.03.2024 | 10-K | 31.12.2023 | 81 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 11.08.2023 | 10-Q | 30.06.2023 | 42 Tage | SEC » |
| 15.05.2023 | 10-Q | 31.03.2023 | 45 Tage | SEC » |
| 31.03.2023 | 10-K | 31.12.2022 | 90 Tage | SEC » |
| 10.11.2022 | 10-Q | 30.09.2022 | 41 Tage | SEC » |
| 11.08.2022 | 10-Q | 30.06.2022 | 42 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 10.03.2022 | 10-K | 31.12.2021 | 69 Tage | SEC » |
| 15.11.2021 | 10-Q | 30.09.2021 | 46 Tage | SEC » |
| 12.08.2021 | 10-Q | 30.06.2021 | 43 Tage | SEC » |
| 13.05.2021 | 10-Q | 31.03.2021 | 43 Tage | SEC » |
| 29.03.2021 | 10-K | 31.12.2020 | 88 Tage | SEC » |
| 12.11.2020 | 10-Q | 30.09.2020 | 43 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 21.10.2025 | Kapitalerhöhung | $250,0 Mio · $84,00/Aktie | SEC » |
| 20.10.2025 | Kapitalerhöhung | $220,0 Mio | SEC » |
| 23.01.2025 | Kapitalerhöhung | $212,0 Mio · $55,00/Aktie | SEC » |
| 21.01.2025 | Kapitalerhöhung | $200,0 Mio | SEC » |
| 15.11.2024 | Kapitalerhöhung | $200,0 Mio | SEC » |
| 14.06.2024 | Kapitalerhöhung | $173,5 Mio · $36,00/Aktie | SEC » |
| 05.12.2023 | Kapitalerhöhung | $192,8 Mio | SEC » |
| 10.10.2023 | Kapitalerhöhung | $59,7 Mio | SEC » |
| 15.06.2023 | Kapitalerhöhung | $129,0 Mio · $49,00/Aktie | SEC » |
| 12.06.2023 | Kapitalerhöhung | $4,57 Mrd | SEC » |
| 14.02.2023 | Kapitalerhöhung | $33,3 Mio · $23,00/Aktie | SEC » |
| 25.01.2023 | Kapitalerhöhung | $100,0 Mio | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 28.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2026 | HV-Einladung | 18.06.2026 Jahres-HV | 22.04.2026 | DEF 14A | SEC » |
| 24.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2025 | HV-Einladung | 11.06.2025 Jahres-HV | 15.04.2025 | DEF 14A | SEC » |
| 01.05.2024 | HV-Einladung | 12.06.2024 Jahres-HV | 15.04.2024 | DEF 14A | SEC » |
| 01.05.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 20.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 20.04.2023 | HV-Einladung | 09.06.2023 Jahres-HV | 14.04.2023 | DEF 14A | SEC » |
| 17.08.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 17.08.2021 | HV-Einladung | 29.09.2021 Jahres-HV | 02.08.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 27.12.2022 | Fusion | 425 | Ziel: Disc Medicine, Inc. | SEC » |
| 13.12.2022 | Fusion | 425 | Ziel: Disc Medicine, Inc. | SEC » |
| 08.12.2022 | Fusion | 425 | Ziel: Disc Medicine, Inc. | SEC » |
| 01.12.2022 | Fusion | S-4/A | Ziel: Disc | SEC » |
| 23.11.2022 | Fusion | S-4/A | Ziel: Disc | SEC » |
| 03.11.2022 | Fusion | S-4/A | Ziel: Disc | SEC » |
| 31.10.2022 | Fusion | 425 | Ziel: Disc Medicine, Inc. | SEC » |
| 07.10.2022 | Fusion | S-4/A | Ziel: Disc · Aktientausch · Umtausch 1,1052 Akt./Ziel-Aktie | SEC » |
| 02.09.2022 | Fusion | S-4 | Ziel: Disc · Aktientausch · Umtausch 1,1052 Akt./Ziel-Aktie | SEC » |
| 10.08.2022 | Fusion | 425 | Ziel: Disc Medicine, Inc. | SEC » |
| 10.08.2022 | Fusion | 425 | Ziel: Disc · Aktientausch · Umtausch 1 Akt./Ziel-Aktie | SEC » |
| 28.01.2021 | Fusion | 425 | Ziel: Gemini Therapeutics, Inc. · Aktientausch · Umtausch 0,218 Akt./Ziel-Aktie | SEC » |
| 19.01.2021 | Fusion | 425 | Ziel: Gemini Therapeutics, Inc. | SEC » |
| 19.01.2021 | Fusion | S-4/A | Ziel: Gemini · Aktientausch | SEC » |
| 15.01.2021 | Fusion | S-4/A | Ziel: Gemini · Aktientausch | SEC » |
| 12.01.2021 | Fusion | S-4/A | Ziel: Gemini · Aktientausch | SEC » |
| 28.12.2020 | Fusion | S-4/A | Ziel: Gemini · Aktientausch | SEC » |
| 07.12.2020 | Fusion | S-4/A | Ziel: Gemini · Aktientausch | SEC » |
| 02.11.2020 | Fusion | S-4 | Ziel: Gemini · Aktientausch | SEC » |
| 20.10.2020 | Fusion | 425 | Ziel: Gemini Therapeutics, Inc. | SEC » |
| 15.10.2020 | Fusion | 425 | Ziel: Gemini Therapeutics · $10,00 Cash + Aktien | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 06.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 of this Current Report on Form 8-K regarding the executive employment agreements is hereby incorporated by… |
| 14.08.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 30.06.2026 | Wesentliche Vereinbarung | 0,30 | 60 | Disc Medicine und Hercules Capital unterzeichneten am 25. Juni 2026 ein Amendment zum Loan Agreement, das die Perioden für zukünftige Kredit… 🔒 | SEC |
| 24.06.2026 | HV-Abstimmung | 0,00 | 30 | Disc Medicine hielt am 18. Juni 2026 seine jährliche Aktionärsversammlung ab. Aktionäre stimmten über drei Vorschläge ab. | SEC |
| 05.05.2026 | Quartalszahlen | 0,00 | 65 | Disc Medicine gab Finanzergebnisse für das erste Quartal 2026 bekannt und lieferte ein Unternehmens-Update. | SEC |
| 27.02.2026 | Sonstiges | -0,82 | 82 | Disc Medicine genehmigt nach einer Complete Response Letter der FDA für seine Bitopertin-NDA einen Restrukturierungsplan zur Anpassung der B… 🔒 | SEC |
| 26.02.2026 | Quartalszahlen | 0,00 | 45 | Disc Medicine gab Finanzergebnisse für Q4 2025 und Geschäftsjahr 2025 bekannt und stellte ein Unternehmens-Update bereit. | SEC |
| 17.02.2026 | Behördliche Maßnahme Red Flag | -0,75 | 78 | Disc Medicine erhielt von der FDA ein Complete Response Letter für bitopertin-NDA. Das Unternehmen diskutiert den regulatorischen Rückschlag… 🔒 | SEC |
| 13.02.2026 | Behördliche Maßnahme Red Flag | -0,80 | 85 | Die FDA erteilt Disc Medicine eine Complete Response Letter für die NDA des Medikaments Bitopertin zur Behandlung von Erythropoietischer Pro… 🔒 | SEC |
| 12.01.2026 | Guidance-Update | 0,50 | 45 | Disc Medicine berichtet vorläufige Kassenbestände von ~$791 Mio. zum 31.12.2025 und gibt Geschäftsziele für 2026 bekannt. Präsentation auf J… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 148 | 74,50 | 11.026 |
| 2026-06-29 | 17.517 | 74,78 | 1.309.921 |
| 2026-06-22 | 73.695 | 70,79 | 5.216.869 |
| 2026-06-15 | 1.326 | 67,99 | 90.155 |
| 2026-06-12 | 13 | 68,08 | 885 |
| 2026-06-10 | 1.390 | 68,34 | 94.993 |
| 2026-06-04 | 1.767 | 70,35 | 124.308 |
| 2026-06-03 | 63 | 68,00 | 4.284 |
| 2026-06-02 | 2.957 | 71,97 | 212.815 |
| 2026-05-28 | 1.675 | 69,76 | 116.848 |
| 2026-05-27 | 1.065 | 68,12 | 72.548 |
| 2026-05-26 | 1.449 | 66,82 | 96.822 |
| 2026-05-22 | 7 | 67,13 | 470 |
| 2026-05-20 | 77 | 64,07 | 4.933 |
| 2026-05-19 | 67 | 66,85 | 4.479 |
| 2026-05-18 | 22 | 66,86 | 1.471 |
| 2026-05-14 | 49 | 70,03 | 3.431 |
| 2026-05-08 | 143 | 67,53 | 9.657 |
| 2026-04-20 | 795 | 71,77 | 57.057 |
| 2026-04-15 | 71 | 70,48 | 5.004 |
| 2026-04-13 | 601 | 66,32 | 39.858 |
| 2026-04-09 | 15 | 66,27 | 994 |
| 2026-03-31 | 5 | 60,78 | 304 |
| 2026-03-30 | 1 | 60,09 | 60 |
| 2026-03-26 | 14.248 | 62,55 | 891.212 |
| 2026-03-25 | 15.670 | 59,61 | 934.089 |
| 2026-03-24 | 469 | 59,11 | 27.723 |
| 2026-03-23 | 321.705 | 58,17 | 18.713.580 |
| 2026-03-19 | 4.420 | 59,14 | 261.399 |
| 2026-03-17 | 37 | 60,89 | 2.253 |
| 2026-03-12 | 10.800 | 63,85 | 689.580 |
| 2026-03-11 | 10.801 | 66,18 | 714.810 |
| 2026-03-10 | 45.244 | 64,23 | 2.906.022 |
| 2026-03-09 | 34.281 | 61,18 | 2.097.312 |
| 2026-03-05 | 21.890 | 61,10 | 1.337.479 |
| 2026-02-27 | 124 | 67,91 | 8.421 |
| 2026-02-25 | 2.686 | 66,20 | 177.813 |
| 2026-02-19 | 9.974 | 64,48 | 643.124 |
| 2026-02-18 | 60.660 | 65,57 | 3.977.476 |
| 2026-02-17 | 38.487 | 55,95 | 2.153.348 |
| 2026-02-06 | 20 | 78,33 | 1.567 |
| 2026-02-05 | 234 | 81,65 | 19.106 |
| 2026-02-03 | 909 | 80,65 | 73.311 |
| 2026-01-30 | 98 | 78,55 | 7.698 |